A Phase 3 interventional study of Moxidectin and Ivermectin in Onchocerciasis, sponsored by Medicines Development for Global Health. Active, not recruiting at 1 site in Democratic Republic of the Congo. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by Medicines Development for Global Health · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this phase 3b study is to determine the safety and efficacy of moxidectin administration twice a year, compared to once a year, in maintaining undetectable levels in skin of O. volvulus microfilaria in skin, the parasite that causes river blindness.
Secondary purposes are to determine the effectiveness of moxidectin compared to ivermectin once or twice a year in maintaining undetectable levels, or reducing levels, of skin microfilaria.
35 studies on the registry are indexed under Onchocerciasis; 7 are open to participants now.
This study's enrollment of 323 is above the median of 216 across 26 interventional studies indexed under Onchocerciasis.
Browse Onchocerciasis studies →Medicines Development for Global Health is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Moxidectin 8mg per oral, administered annually for 24 months
Drug: Moxidectin
Moxidectin 8mg per oral, administered biannually for 24 months
Drug: Moxidectin
Ivermectin (approximately) 150 micrograms/kg per oral, administered annually for 24 months
Drug: Ivermectin
Ivermectin (approximately) 150 micrograms/kg per oral, administered biannually for 24 months
Drug: Ivermectin
2mg tablets, encapsulated for blinding
3mg tablets, encapsulated for blinding
Proportion of moxidectin annual and biannual recipients with sustained microfilarial response at month 12
Proportion of recipients with zero Onchocerca volvulus microfilariae/mg skin at all post-treatment timepoints to month 12
Time frame: Up to 12 months
Incidence and severity of adverse events
Incidence and severity of adverse events, vital signs and liver function tests
Time frame: Up to 36 months
Proportion of participants in all dose groups with sustained microfilariae response
Proportion of participants with zero Onchocerca volvulus microfilariae/mg skin
Time frame: 6 months, 12 months, 18 months, 24 months, 30 months, 36 months
Sustained ocular microfilariae response in all dose groups
Proportion of participants with 0 live O. volvulus microfilariae in the anterior chambers of the eyes at all post-Baseline assessments in those with liver ocular microfilariae before the first treatment
Time frame: 6 months, 12 months, 18 months, 24 months, 30 months, 36 months
Skin microfilarial density in all dose groups
Mean, median and percentage reduction Onchocerca volvulus microfilariae/mg skin from baseline
Time frame: 6 months, 12 months, 18 months, 24 months, 30 months, 36 months
Ocular microfilariae response in all dose groups
Proportion of participants in all dose groups with 0 Onchocerca volvulus microfilariae/mg skin and 0 live microfilariae in the anterior chambers of the eyes each timepoint
Time frame: 6 months, 12 months, 18 months, 24 months, 30 months, 36 months
Mean skin microfilariae density at each post-Screening assessment
Mean and mean change from baseline of Onchocerca volvulus microfilariae/mg skin
Time frame: 6 months, 12 months, 18 months, 24 months, 30 months, 36 months
Signs and symptoms of onchocerciasis in all dose groups
Proportion of participants with signs and symptoms of onchocerciasis with these signs and symptoms at baseline.
Time frame: 6 months, 12 months, 18 months, 24 months, 30 months, 36 months
Viability and fertility of male and female macrofilariae in all dose groups
Histopathological assessment of male and female macrofilariae excised from participants with palpable nodules
Time frame: 36 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from May 2021 to primary completion in Jul 2024, 38 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Moxidectin · Ivermectin
Medicines Development for Global Health